Q3 2024 Earnings Call Transcript November 8, 2024 Amneal Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

Amneal Pharmaceuticals Inc (AMRX) reports robust Q3 performance with significant strides in new markets and innovative product launches.

The company aims to create long-term value for stakeholders by leveraging its expertise and expanding its product pipeline. Trending Articles Amneal Pharmaceuticals NewsMORE Related Stocks Indices ...

Amneal Pharmaceuticals, Inc. (AMRX), a generics and specialty pharmaceutical company, on Friday reported net loss for the third ...

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Get Free Report) hit a new 52-week high on Monday after StockNews.com upgraded the stock from a buy rating to a strong-buy rating. The company traded as ...

On Friday, Amneal Pharmaceuticals Inc (NASDAQ:AMRX) reported third-quarter adjusted EPS of $0.16, down from $0.19 a year ago, ...

Amneal Pharmaceuticals logged a big jump in revenue from gains in its generic and specialty drug portfolio, though higher interest costs swung it to a net loss. The drugmaker posted a loss of $156,000 ...

Private Advisor Group LLC lowered its position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 48.3% in the third quarter, according to its most recent 13F filing with the Securities ...

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den ...

Generic Drug-Focused Amneal Beats Q3 Expectations ... JP Morgan assesses the specialty pharma sector, highlighting robust fundamentals and new product excitement. Key focus on Teva, Organon ...

From our award-winning Content Services offerings, integrated media newsroom and microsite products ... at 06:05 Amneal Reports Third Quarter 2024 Financial Results Amneal Pharmaceuticals, Inc.

On 29 October 2024, the Board of Directors of Tetragon declared a dividend of U.S.$ 0.11 (11.00 cents) per share in respect of the third quarter of 2024. The ex-dividend date is 1 November 2024. The ...